Author: uniQure Inc.

Posted Date:

May 5, 2026

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

uniQure Inc.

May 5, 2026
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease

uniQure Inc.

April 30, 2026
uniQure to Announce First Quarter 2026 Financial Results

uniQure Inc.

April 28, 2026
uniQure Announces 2025 Financial Results and Provides Recent Company Updates

uniQure Inc.

March 2, 2026
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

uniQure Inc.

March 2, 2026
uniQure to Announce 2025 Financial Results

uniQure Inc.

February 23, 2026
uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

uniQure Inc.

February 8, 2026